Skip to main content
Home

Main navigation

  • Our Company
    • Who we are
    • Senior Leadership Team
    • Board of Directors
    • Sustainability
    • Awards and Recognition
    • Virtual Company Tour
  • Our Solutions
    • AGROBODY® Foundry
    • Product pipeline
    • Evoca®
    • Field trials
  • Investors
    • Press releases
    • Financial information
    • Stock Information
    • Shareholder information
    • Corporate governance
    • Events
    • Presentations
    • IPO
  • Partnering
  • News & Events
    • Press releases
    • Events
    • Stay in touch
    • Message from our CEO
  • Careers
    • Open Positions
    • Vision & Values
    • What our employees say
    • Benefits and wellbeing
  • Contact

User account menu

  • Log in
Go back

Biotalys Announces Expected Successful Closing of its Initial Public Offering

Press Release

Social Menu

  • Twitter
  • LinkedIn
  • Email

Press releases

Biotalys Achieves Critical Manufacturing Milestone for First Commercial Biofungicide EVOCA® NG

November 9, 2026

Biotalys’ First Commercial Biofungicide EVOCA® NG Approved for Large-Scale Commercial Field Trials in the Netherlands

November 3, 2026

Press Release - Regulated Information

October 13, 2026
Discover all press releases

Footer navigation (primary)

  • Our Company
    • Who we are
    • Senior Leadership Team
    • Board of Directors
  • Our Solutions
    • AGROBODY® Foundry
    • Product pipeline
  • Investors

Footer navigation (secondary)

  • Partnering
  • Media
    • Press releases
    • Events
    • Download section
    • Stay in touch
  • Contact

Home

Biotalys NV
Buchtenstraat 11
Ghent 9051, Belgium
Phone: +32 (0)9 274 5400

info@biotalys.com

© Copyright 2026 Biotalys NV | Privacy Policy | Cookie Policy | General Purchasing Conditions